Folotyn for Non-Hodgkin's Lymphoma Horseheads NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

AREF AGHELI, MD
(607) 937-3509
114 Columbia Street
Corning, NY
SERGE DAUPHIN, MD
(607) 737-8165
600 Roe Avenue
Elmira, NY
Roberto Mauri, MD
607-739-3644
859 Broadway St
Elmira, NY
William Thomas Muuse, MD
607-737-8165
600 Roe Ave
Elmira, NY
Nejat Akbiyik, MD
100 E 14th St
Elmira Heights, NY
HARISH MALHOTRA, MD
(570) 882-3025
114 Columbia Street
Corning, NY
ROBERT ABDERHALDEN, MD
(607) 737-8165
600 Roe Avenue
Elmira, NY
Patrick Raymond Bergevin, MD
607-937-3100
130 Center Way
Corning, NY
Robert Thomas Abderhalden, MD
607-737-8165
600 Roe Ave
Elmira, NY
R Y Byland, MD
607-737-8120
100 E 14th St
Elmira, NY
Data Provided by:
  

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Green Tea and Hematologic Malignancies Horseheads NY
Read more about Green Tea May Lower the Risk of Hematologic Malignancies.
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Horseheads NY